Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDORMS have been successful with 3 Clinical Trials (BioPatch, MANTIS and NINJA) being awarded.

BioPatch

NIHR i4i committee has approved Prof Andrew Carr’s application entitled “A novel electrospun patch to augment rotator cuff tendon repair” - Oxford BioPatch. The Oxford Biopatch is an innovative solution for rotator cuff repair which promotes rapid regrowth of tendon tissue and could transform the success of shoulder repair operations. Speaking about the award Prof Carr stated that “The monies from the NIHR are invaluable to investigate whether a nanofiber surgical patch invented in Oxford can improve the outcome of surgery for tendon repair in the shoulder and we are looking forward to discovering if the technology can improve patient recovery”.

MANTIS

NIHR HTA committee has approved Prof Sion Glyn-Jones application entitled “Managing Avascular Necrosis Treatments: An Interventional Study” MANTIS. This will be looking at the debilitating affect that Avascular Necrosis (AVN) of the hip occurs in younger people and how this may be managed by an effective drug treatment. Lead Researcher Prof Sion Glyn Jones states that “With this support from NIHR we have the opportunity to find an effective drug treatment for this condition could improve the quality of life for thousands of young people”

NINJA

NIHR RfPB committee has approved Prof Abhilash Jain and his application entitled “Nail Injury Analysis Trial” NINJA. This will be looking into childrens’ fingertip injuries which is the most common surgically treated paediatric hand injury with 10,000 operations performed every year in the UK. Despite this there are no published randomized controlled trials (RCT) looking at surgical interventions and NINJA is the first multi-centre RCT looking at ways to improve surgical outcomes in these patients. On receiving confirmation of the award Prof Jain stated “This award from NIHR will allow us to evaluate two differing repair techniques with the intention of advising best practice to clinicians for future Injuries”.

Our Team

Further Information on the Trials

Similar stories

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.

NDORMS researchers awarded for Dupuytren research

Awards Hand Kennedy Main

Three NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.

Hope for rheumatoid arthritis patients who are non-responsive to anti-TNF

Arthritis Kennedy Main

New research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).

A new study maps the expression of innate immune receptors during the course of arthritis

Arthritis Kennedy Main

The research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.

International Women's Day

Department Main

It’s International Women's Day! This year’s theme is #Choosetochallenge. We’re celebrating some of the amazing women at NDORMS, and asking them what changes they’d like to see in medical sciences over the next 100 years.

Patients and carers invited to join new group helping to shape research and treatment of bones, muscles and joints

Main PPI

Oxford’s newest patient partner group, OPEN ARMS launches today to explore the causes, treatment and care for patients with musculoskeletal conditions. Its first three patient partners explain why they are involved and invite other members of the public to join the team.